Vagelos, the Merck executive, should invest on the development of the

drug. And if the drug would be a success, they should distribute it to the Third
World countries, which were affected by the Onchocerca volvulus.

Given the situation, none of the countries that were affected can afford
the cure; hence, they could not recover their investment. But despite this
situation, they should continue in developing the drug for the said disease. The
reason for the decision is Mercks overall corporate philosophy.

It is stated in their vision:

To discover, develop and provide innovative products and
services that save and improve lives around the world.

The health of the people is their priority rather than the profits they
would receive. George W. Merck also proves this vision, in his statement that,
"We try never to forget that medicine is for the people, it is not for the profits.
The profits follow, and if we have remembered that, they have never failed to
appear. The better we have remembered it, the larger they have been."
Merck is committed to philanthropy and corporate social responsibility.
Which constitutes for the reason that they should continue in investing in the
drug and eventually distribute it, if it is successful, even if it would be a donation
to the affected countries.